文献速递冠心病

赛庚啶对心肌梗死后二尖瓣重构及反流的影响

Effects of Cyproheptadine on Mitral Valve Remodeling and Regurgitation After Myocardial Infarction.
PubMed 文献 · J Am Coll Cardiol · 2022-01-01

结果显示赛庚啶降低梗死后5-HT水平,减轻二尖瓣纤维化重构,使瓣叶尺寸增加更明显且反流分数显著降低,提示其可能预防缺血性二尖瓣反流。

要点

  • 赛庚啶可降低心梗后升高的5-HT水平,抑制瓣膜纤维化重构。
  • 治疗组90天反流分数显著低于未治疗组(2%±6% vs 16%±7%)。
  • 赛庚啶组二尖瓣瓣叶尺寸增加更明显,且体外实验证实其可抑制间质细胞ECM基因过表达。

核心结论

  • 下壁心梗后给予赛庚啶可降低5-HT水平,预防二尖瓣纤维化重构,并与瓣叶尺寸增加更大及反流更少相关。

研究设计与样本

  • 补充体外实验:瓣膜间质细胞暴露于实验动物心梗前及心梗后血清。

主要发现

  • 未治疗组心梗后5-HT水平升高,赛庚啶组未见升高。
  • 两组梗死面积相似(11±3 g vs 9±5 g;P=0.414)。
  • 90天反流分数:心梗组16%±7% vs 赛庚啶组2%±6%(P=0.0001)。
  • 心梗后瓣叶尺寸增加:赛庚啶组+40%±9% vs 心梗组+22%±12%(P=0.001)。
  • 体外实验:心梗后血清使二尖瓣间质细胞ECM基因过表达,但经治疗动物的心梗后血清无此效应。

临床怎么用

  • 赛庚啶(5-HT2BR拮抗剂)可能作为心梗后预防缺血性二尖瓣反流的潜在药物干预策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Ischemic mitral regurgitation (MR) is primarily caused by left ventricle deformation, but leaflet thickening with fibrotic changes are also observed in the valve. Increased levels of 5-hydroxytryptamine (5-HT; ie, serotonin) are described after myocardial infarction (MI); 5-HT can induce valve fibrosis through the 5-HT type 2B receptor (5-HT2BR). OBJECTIVES: This study aims to test the hypothesis that post-MI treatment with cyproheptadine (5-HT2BR antagonist) can prevent ischemic MR by reducing the effect of serotonin on mitral biology. METHODS: Thirty-six sheep were divided into 2 groups: inferior MI and inferior MI treated with cyproheptadine (0.5 mg/kg/d). Animals were followed for 90 days. Blood 5-HT, infarct size, left ventricular volume and function, MR fraction and mitral leaflet size were assessed. In a complementary in vitro study, valvular interstitial cells were exposed to pre-MI and post-MI serum collected from the experimental animals. RESULTS: Increased 5-HT levels were observed after MI in nontreated animals, but not in the group treated with cyproheptadine. Infarct size was similar in both groups (11 ± 3 g vs 9 ± 5 g; P = 0.414). At 90 days, MR fraction was 16% ± 7% in the MI group vs 2% ± 6% in the cyproheptadine group (P = 0.0001). The increase in leaflet size following MI was larger in the cyproheptadine group (+40% ± 9% vs +22% ± 12%; P = 0.001). Mitral interstitial cells overexpressed extracellular matrix genes when treated with post-MI serum, but not when exposed to post-MI serum collected from treated animals. CONCLUSIONS: Cyproheptadine given after inferior MI reduces post-MI 5-HT levels, prevents valvular fibrotic remodeling, is associated with larger increase in mitral valve size and less MR.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Marsit, Clavel, Paquin, et al. Effects of Cyproheptadine on Mitral Valve Remodeling and Regurgitation After Myocardial Infarction. J Am Coll Cardiol. 2022. PMID: 35902173. doi:10.1016/j.jacc.2022.05.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。